Asset / Drug

TPX-115

Drug and asset intelligence for TPX-115 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Recent signals(1)

ClinicalJune 19, 2026

Tego Science initiates study on TPX-115 for Partial-Thickness Rotator Cuff Tear

Tego Science is conducting a study to evaluate the efficacy and safety of TPX-115, an allogeneic dermal fibroblast therapy, in patients with Partial-Thickness Rotator Cuff Tear.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— TPX-115

Monitor the outcomes of the primary and secondary endpoints, particularly the improvement in the Constant-Murley Score and safety data.

June 19, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Orthopedics →

Orthopedics · Regenerative Medicine →

Regenerative Medicine →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.